1-Isopropyl-2-methyl-5-nitroimidazol | 33003-18-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-Isopropyl-2-methyl-5-nitroimidazol
• 英文别名: 1-isopropyl-2-methyl-5-nitro-1H-imidazole；2-methyl-5-nitro-1-propan-2-ylimidazole
• CAS: 33003-18-8
• 化学式: C₇H₁₁N₃O₂
• mdl: MFCD21339133
• 分子量: 169.183
• InChiKey: FHZFIUJNLJGRBL-UHFFFAOYSA-N

物化性质

• 沸点：
  309.3±15.0 °C(Predicted)
• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  63.6
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Nitroheteroaryl-containing rifamycin derivatives
  申请人：Ding Charles Z.

  公开号：US20080139577A1

  公开（公告）日：2008-06-12

  Substituted rifamycin derivatives in which a nitroimidazole, nitrothiazole or nitrofuran pharmacophore is covalently bonded to a rifamycin, methods of using the rifamycin derivatives, and pharmaceutical compositions containing the rifamycin derivatives are disclosed. Methods of synthesizing these substituted rifamycin derivatives are also disclosed. The rifamycin derivatives possess antibacterial activity, and are effective against a number of human and veterinary pathogens in the treatment of bacterial diseases.

  本发明公开了替代利福霉素衍生物，其中硝基咪唑、硝基噻唑或硝基呋喃药效团与利福霉素共价键合，公开了使用该利福霉素衍生物的方法以及含有该利福霉素衍生物的制药组合物。还公开了合成这些替代利福霉素衍生物的方法。该利福霉素衍生物具有抗菌活性，并且在治疗细菌性疾病中对许多人类和兽医病原体有效。
• Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, the synthesis and uses thereof as antibacterial agents
  申请人：Sanchez Muriel

  公开号：US20070060558A1

  公开（公告）日：2007-03-15

  The invention concerns an aminoquinoline-antibiotic hybrid compound of general formula (I): Q—(Y 1 ) p —(U) p —(Y 2 ) p -A: wherein Q represents an aminoquinoline, (Y 1 ) p (U) p —(Y 2 ) p″ is an optional spacer and A is an antibiotic residue. The invention enables the antibiotic residue activity to be unexpectedly enhanced.

  本发明涉及一种氨基喹啉-抗生素杂合物，其一般式为(I)：Q—(Y1)p—(U)p—(Y2)p-A，其中Q代表氨基喹啉，(Y1)p(U)p—(Y2)p″是可选的间隔基，A为抗生素残基。本发明使得抗生素残基的活性得到了意外的增强。
• SACCHARIDE ANALOGS AND AGENTS FOR THE DIAGNOSIS AND THERAPY OF BACTERIAL INFECTIONS
  申请人：Emory University

  公开号：US20170274087A1

  公开（公告）日：2017-09-28

  This disclosure relates saccharide analogs such as thiomaltose-based analogs for targeting bacteria and related uses. In certain embodiments, the disclosure relates to methods of transferring a molecule of interest into bacteria comprising mixing bacteria with a non-naturally occurring conjugate, wherein the conjugate comprises a thiomaltose-based analog and a molecule of interest under conditions such that the conjugate is transported across the bacterial cell wall. In certain embodiments, the molecule of interest can be a tracer or an antibiotic.
• US7678791B2
  申请人：——

  公开号：US7678791B2

  公开（公告）日：2010-03-16
• [EN] NITROHETEROARYL-CONTAINING RIFAMYCIN DERIVATIVES<br/>[FR] DÉRIVÉS DE RIFAMYCINE CONTENANT DU NITROHÉTÉROARYL
  申请人：CUMBRE PHARMACEUTICALS INC

  公开号：WO2008008480A2

  公开（公告）日：2008-01-17

  [EN] Substituted rifamycin derivatives in which a nitroimidazole, nitrothiazole or nitrofuran pharmacophore is covalently bonded to a rifamycin, methods of using the rifamycin derivatives, and pharmaceutical compositions containing the rifamycin derivatives are disclosed. Methods of synthesizing these substituted rifamycin derivatives are also disclosed. The rifamycin derivatives possess antibacterial activity, and are effective against a number of human and veterinary pathogens in the treatment of bacterial diseases.
  [FR] La présente invention concerne des dérivés de rifamycine substitués dans lesquels un nitroimidazole, nitrothiazole ou nitrofurane pharmacophore est lié par covalence à une rifamycine, des procédés d'utilisation des dérivés de rifamycine, et des compositions pharmaceutiques contenant les dérivés de rifamycine. L'invention concerne aussi des procédés pour synthétiser ces dérivés de rifamycine substitués. Les dérivés de rifamycine possèdent une activité antibactérienne, et sont efficaces contre un certain nombre de pathogènes humains et vétérinaires dans le traitement de maladies bactériennes.